ChemoCentryx (CCXI) Reports Mixed FDA AdCom Vote For Avacopan
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms
May 7, 2021 9:36 AM EDTShares of ChemoCentryx (NASDAQ: CCXI) crashed 55% in pre-open Friday after the Food and Drug Administration (FDA) raised concerns over the approval application of the product avacopan.
We are grateful to the Committee for their careful deliberations and look forward to working with the FDA as its review of our application continues, said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. Discussion from patients and clinicians during the public forum portion of the meeting underscored the need for new treatment options.
The FDA is primarily concerned that the therapy could not... More
Raymond James Downgrades ChemoCentryx (CCXI) to Outperform
May 7, 2021 7:38 AM EDTRaymond James analyst Steven Seedhouse downgraded ChemoCentryx (NASDAQ: CCXI) from Strong Buy to Outperform with a price target of $51.00 (from $120.00).
The analyst commented, "To be clear, our downgrade to Outperform from Strong Buy is based on reduced conviction in avacopan being approved by July 7 PDUFA given Thursdays AdCom discussion and vote. However, if approved we still think avacopan is a... More
ChemoCentryx (CCXI) sinks 45% as trading resumes following mixed FDA AdCom
May 7, 2021 7:15 AM EDTChemoCentryx (NASDAQ: CCXI) sinks 45% as trading resumes following mixed FDA AdCom.
... MoreUPDATE: Stifel Downgrades ChemoCentryx (CCXI) to Hold
May 7, 2021 4:01 AM EDT(Updated - May 7, 2021 5:14 AM EDT)
Stifel analyst Dae Gon Ha downgraded ChemoCentryx (NASDAQ: CCXI) from Buy to Hold with a price target of $26.00 (from $93.00).
THe analyst comments "We are downgrading CCXI to Hold (from Buy) with a reduced TP $26 (from $93 previously) following a... More
UPDATE: JPMorgan Downgrades ChemoCentryx (CCXI) to Underweight
May 7, 2021 4:01 AM EDT(Updated - May 7, 2021 5:12 AM EDT)
JPMorgan analyst Anupam Rama downgraded ChemoCentryx (NASDAQ: CCXI) from Neutral to Underweight with a price target of $17.00 (from $57.00).
The analyst comments "We hold an Underweight rating on CCXI shares. ChemoCentryx is a biotechnology company with a focus on developing oral drugs that target the chemokine system, which is... More